Apimeds Pharmaceuticals US (APUS) EBITDA (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted EBITDA of -$7.0 million for Q4 2025, down 281.73% on a QoQ basis from -$1.8 million in Q3 2025, and down 2454.32% year-over-year from $299026.3 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) EBITDA (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's EBITDA history runs 2 years deep, the most recent figure standing at -$7.0 million for Q4 2025.
- Quarterly EBITDA fell 2454.32% year-over-year to -$7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.9 million (down 834.25% YoY) and the FY2025 annual result came in at -$11.9 million, down 834.25% from the prior year.
- EBITDA was -$7.0 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.8 million in the prior quarter.
- Across five years, EBITDA topped out at -$271726.0 in Q1 2024 and bottomed at -$7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 61.48 Mn | 61.48 Mn | - | -7.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.04 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -2.66 Mn |
| Mar 31, 2025 | -364,368.00 |
| Dec 31, 2024 | -275,613.00 |
| Sep 30, 2024 | -299,999.00 |
| Jun 30, 2024 | -427,757.00 |
| Mar 31, 2024 | -271,726.00 |